On February 21, 2023 TC BioPharm(Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, reported the publication of a paper entitled, "A Phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia" in Clinical Lymphoma, Myeloma and Leukemia, a monthly peer reviewed journal (Press release, TC Biopharm, FEB 21, 2023, View Source [SID1234627487]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The article highlights the abilities of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia. The publication can be accessed online through the portal ScienceDirect at "A phase I trial of allogeneic γδ T lymphocytes from haploidentical donors in patients with refractory or relapsed acute myeloid leukemia. – ScienceDirect"
"I feel privileged to be part of the team that achieved the successful publication on our phase I trial using OmnImmune (haploidentical allogeneic γδ T lymphocytes) in advanced AML patients," said Dr. Emilio Cosimo, Director of Product Development. "The study shows the safety of this type of cell therapy and is the basis for TCB’s next steps in the allogeneic cell therapy sector."
Dr. Jan Vydra, Institute Of Hematology And Blood Transfusion, commented, "The results of our phase I clinical trial of γδ T cell immunotherapy of advanced AML support further research and development of this cell therapy platform, as it was shown to be both safe and feasible in this setting."
"This marks the first publication generated by TC Biopharm, a hallmark moment for our company and our team to be recognized within the industry," said Bryan Kobel, CEO of TC BioPharm. "I’d like to thank Dr. Vydra for all his hard work running the study and our former clinical director, Tomasz Zaremba, as well as Angela Scott, Dr. Mike Leek, Dr. Sebastian Wanless, Dr. Emilio Cosimo and the rest of the contributors. We look forward to additional publications in the future from our team."